$MRNA

The latest Sainteur stock news on MRNA, newest first.

• Moderna slides after its cancer vaccine data leaked early, even though the results looked strong

  Partial Phase 3 results with Merck slipped out ahead of Saturday's ESMO presentation. The full data showed a 42% cut in the risk of recurrence or death, but after a 530%-plus run this year, analysts say expectations were higher still.

  Equities · Oct 23, 2026, 8:45 PM EDT · Marcus Rodriguez